MODELING OF EX VIVO INTERNALIZATION METHOD OF WATER- SOLUBLE ANTICANCER DRUGS IN SMALL INTESTINE USING CHEMILUMINESCENCE

Introduction. the ability of the small intestine (internalization) to absorb water-soluble anticancer cytostatics determines the possibility of their oral administration. the ex-vivo express method that simulates the internalization of substances using a modified technique of an isolated «inverted» segment of the rat small intestine with flash chemiluminescence is adequate to solve the problem. Objectives: to evaluate the absorption of the new water-soluble anticancer cytostatics with different properties from the rat small intestine for preclinical study by oral administration. Material and methods. conjugated with acridinium (Acridinium NHS Ester, Toronto Research Chemicals, Canada) cytostatics were studied: low molecular weight (1) anthrafuran-acridinium (MW 0.8 kDa) and high molecular weight (2) aimpila-acridinium (MW 105 kDa) and (3) L-lysine-α-oxidase (LO-acridinium, MW 122 kDa). absorption was determined in a modified model of an isolated «inverted» segment of the rat small intestine using flash-chemiluminescence with the calculation of the relative light units (RLu). Results. It was shown that the absorption level of acridinium-conjugated cytostatics depending on molar concentration ranged from 55 % (1) to 1.7–11 % (2, 3) and 2500 (1) to 9.2–188 nmol/l (2, 3), respectively. the level of internalized anthrafuran-acridinium (55 %) was consistent with the known value of the effective non-conjugated cytostatic oral dose, which was two times higher than equitherapeutical parenteral dose: 100 mg/kg vs 50 mg/kg. Conclusion. the data obtained allow us to consider ex vivo express method for preclinical study of the various water-soluble anticancer cytostatics for screening and identification of an opportunity for oral administration and estimation of starting dose. the method has a good correlation with in vivo tests and economically favorable due to a quick response and small number of the tested agent.

cytostatics, internalization, rat small intestine, express-method, ex vivo

1. Yan S., L. Yang., Lu L., Guo Q., Hu X., Yuan Y., Li Y., Wu M., Zang J. Improved pharmacokinetic characteristics and bioactive effects of anticancer enzyme delivery systems. Expert opinion on drug metabolism and toxicology. 2018; 14: 951–960. doi: 10.1080/17425255.2018.1505863.

2. Mazzaferro S., Bouchemal K., Ponchel G. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today. 2013 Jan; 18(1–2): 25–34. doi: 10.1016/j.drudis.2012.08.004.

3. Sparreboom A., De Jonge M. J. A., Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer. 2002; 38: 1822. doi: 10.1016/S0959-8049(01)00322-7.

4. Andronova N.B., Tcherkassova J.R., Tsurkan S.A., Smirnova G.B., Treshalina H.M. Evaluation of the internalization of AFP-containing noncovalent complexes AIMPILA in the rat model of the isolated segment of rat small intestine. Russian Journal of Oncology 2016; 21 (6): 308–311.(in Russian). doi: 10.18821/1028-9984-2016-21-6-308-311.

5. Tcherkassova J., Abramovich C., Moro R., Chen C., Schmit R., Gerber A., Moro R. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol. 2011 Aug; 32(4): 831–8. doi: 10.1007/s13277-011-0186-1.

6. Réti-Nagy K., Malanga M., Fenyves E., Szente L., Vámosi G., Váradi J., Bácskay I., Fehér P., Ujhelyi Z., Róka E., Vecsernyés M., Balogh G., Vasvári G., Fenyvesi F. Endocytosis of fluorescent cyclodextrins by intestinal Caco-2 cells and its role in paclitaxel drug delivery. Int J Pharm. 2015 Dec 30; 496(2): 509–17. doi: 10.1016/j.ijpharm.2015.10.049.

7. Tsurkan S., Tcherkassova J., Gorbunova V., Treshalina H. New drug AIMPILA targeted to AFP receptor: Oral anticancer therapy and biodistribution in vivo. J Clin Oncol. 2018: 36 (15_suppl): e24232–24232. doi: 10.1200/JCO.2018.36.15.

8. Pokrovsky V.S., Treshalina H.M., Lukasheva E.V., Sedakova L.A., Medentzev A.G., Arinbasarova A.Yu., Berezov T.T. Enzymatic properties and anticancer activity of L-lysine alpha-oxidase from Trichoderma cf. aureoviride Rifai ВКМF-4268D. Anticancer Drugs. 2013 Sep; 8(24): 846–851. doi: 10.1097/CAD.0b013e328362fbe2.

9. Pokrovsky V.S., Treshalina Е.M., Lukasheva E.V., Sedakova L.A. Development of intravenous administration of L-lysinealpha-oxidase from Trichoderma CF. Aureoviride Rifai BKMF-4268 regime controlled by safety and efficacy of treatment. Russian Journal of Oncology. 2013; 2: 10–14. (in Russian).

10. Kusakabe H., Kodama K., Kuninaka F., Yoshino Y., Misono H., Soda K. A new antitumor enzyme, L-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties. J Biol Chem. 1980. 255: 976–981.

11. Lukasheva E.V., Ribakova Y.S., Fedorova T.N., Makletsova M.G., Arinbasarova A.Y., Medentzev A.G., Berezov T.T. Isolation and properties of L-Lysine α-oxidase from Trichoderma cf. aureoviride Rifai ВКМ F-4268D. Microbiologia. 2012; 81: 594–594. doi: 10.1134/S0026261712050037.

12. Asano Y., Yasukawa K. Identification and development of amino acid oxidases. Curr Opin Chem Biol. 2019 Apr; 49: 76–83. doi: 10.1016/j.cbpa.2018.10.020.

13. Shchekotikhin A.E., Treshalina H.M., Treschalin I.D. Oral anticancer agents and method of treatment of cancer. Russian patent № 2639479. 2017. (In Russian).

14. Treshalina H.M., Romanenko V.I., Kaluzhny D.N., Treshalin M.I., Nikitin A.A., Tikhomirov A.S., Shchekotikhin A.E. Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. Eur J Pharm Sci. 2017 Nov 15; 109: 631–637. doi: 10.1016/j.ejps.2017.09.025.

15. Tikhomirov A.S., Lin C.Y., Volodina Y.L., Dezhenkova L.G., Tatarskiy V.V., Schols D., Shtil A.A., Punit Kaur, Pin Ju Chueh, Shchekotikhin A.E. New antitumor anthra [2, 3-b] furan-3-carboxamides: Synthesis and structure-activity relationship. Eur J Med Chem. 2018 Mar 25; 148: 128–139. doi: 10.1016/j.ejmech.2018.02.027.

16. Zavedos. Medicinal guide GEOTAR [Internet]. URL: https://www.lsgeotar.ru/zavedos-3422.html. (cited: 16.04.2019). (in Russian).

17. Amin M., Pourshohodb A., Kheirollahb A., Afrakhtehb M., Gholami-Borujenic F., Zeinalid M., Jamalanef M. Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumabconjugated liposomes. J Drug Delivery Sci Technol. 2018; 47: 209–214. doi: 10.1016/j.jddst.2018.07.017